



OUR MISSION

The Society for Immunotherapy of Cancer (SITC) is the world's leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. SITC is a 501(c)(3) not-for-profit medical professional society of influential research scientists, physician scientists, clinicians, patients, patient advocates, government representatives and industry leaders. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word "cure" a reality for cancer patients everywhere.

EXPANSIVE REACH


SITC's community of scientists, practitioners and healthcare professionals spans the country.

Membership

- 47 U.S. states
- 56 comprehensive cancer centers represented

A Membership Driven Society

- 350 volunteers contributing across SITC
- 29 committees and taskforces
- 78 SITC champions at cancer care institutes



STRATEGIC GOALS

SITC's vision is for 100 novel IO agents approved by 2034!



Professional Standards



Policy and Advocacy



Science and Research



Global Access and Impact



Education and Scientific Exchange



Leadership Development

COLLABORATION

- The Society for Immunotherapy of Cancer (SITC) is committed to taking a 'big tent' approach to overcoming the largest hurdles in the field
- The society maintains strong relationships with cancer research & medical institutions, professional & advocacy associations and government agencies
- Leveraging these relationships to develop the highest quality scientific meetings, education programs and scientific resources

IMMUNOTHERAPY BY THE NUMBERS

Advancing the Science

Currently **100+** clinical trials ongoing in cancer immunotherapy

Potential for Cure

50% of metastatic Melanoma patients **alive at 10 years***

Growth in the Field

147 approvals for immunotherapies in cancer since 2011

Increased Options

Immunotherapy indications for **33 different diseases**

*Dana Farber Cancer Institute - "Long-term Metastatic Melanoma Survival Dramatically Improves on Immunotherapy"



X: @sitcancer



LinkedIn: [linkedin.com/company/society-for-immunotherapy-of-cancer-sitc](https://www.linkedin.com/company/society-for-immunotherapy-of-cancer-sitc)



Bluesky: [sitcancer.bsky.social](https://bsky.app/profile/sitcancer.bsky.social)



YouTube: [youtube.com/sitcancer](https://www.youtube.com/sitcancer)



Facebook: [facebook.com/sitcancer](https://www.facebook.com/sitcancer)



[sitcancer.org](https://www.sitcancer.org)